Revenue: As of FY2027 Q1, the actual value is USD 265.71 M, beating the estimate of USD 250.32 M.

EPS: As of FY2027 Q1, the actual value is USD 0.61, missing the estimate of USD 0.84.

EBIT: As of FY2027 Q1, the actual value is USD 52.49 M.

Overview of Fiscal 2027 First Quarter Performance

Prestige Consumer Healthcare Inc. reported total revenues of $265.7 million for the first quarter of fiscal 2027, an increase of 6.5% compared to $249.5 million in the prior year period. Organic sales growth for the quarter was 3.2%, surpassing expectations. Net income for the first quarter of fiscal 2027 totaled $29.2 million, a decrease from $47.5 million in the comparable prior year period. Adjusted non-GAAP net income for the first quarter of fiscal 2027 was $46.5 million.

Gross Profit

Prestige Consumer Healthcare Inc.’s gross profit was $136.2 million in Q1 fiscal 2027, down from $140.3 million in Q1 fiscal 2026. The GAAP Gross Profit as a percentage of GAAP Total Revenue was 51.3% in Q1 fiscal 2027, compared to 56.2% in Q1 fiscal 2026. Non-GAAP Adjusted Gross Margin was $146.2 million, with a Non-GAAP Adjusted Gross Margin as a Percentage of GAAP Total Revenues of 55.0% for Q1 fiscal 2027.

Operating Expenses

Total operating expenses increased to $83.7 million in Q1 fiscal 2027 from $68.6 million in Q1 fiscal 2026. Advertising and marketing expenses were $34.7 million in Q1 fiscal 2027, a slight decrease from $34.9 million in the prior year. General and administrative expenses rose to $43.3 million in Q1 fiscal 2027 from $28.5 million in Q1 fiscal 2026. Non-GAAP Adjusted General and Administrative Expense was $30.5 million for Q1 fiscal 2027, compared to $28.5 million in Q1 fiscal 2026.

Operating Income

Operating income for Q1 fiscal 2027 was $52.5 million, a decrease from $71.8 million in Q1 fiscal 2026.

Net Income

Net income was $29.2 million in Q1 fiscal 2027, down from $47.5 million in the prior year period.

Cash Flow

Net cash provided by operating activities was $70.8 million for Q1 fiscal 2027, a decrease from $79.0 million in the prior year comparable period. Non-GAAP adjusted free cash flow increased to $83.7 million in Q1 fiscal 2027, up from $78.2 million in the prior year’s first quarter.

Unique Metrics

Prestige Consumer Healthcare Inc.’s net debt position was approximately $2 billion as of June 30, 2026. Subsequent to the quarter, the company issued $400 million of new 6.25% senior notes due 2034, replacing notes previously due in fiscal 2028, which extends the closest debt maturity to 2031. The Breathe Right® acquisition contributed an incremental $6 million in revenue during the quarter.

Segment Revenue

North American OTC Healthcare: Segment revenues increased by 6.4% to $226.2 million in Q1 fiscal 2027, compared to $212.6 million in the prior year quarter. The contribution margin for this segment was $87.0 million in Q1 fiscal 2027, down from $91.4 million in Q1 fiscal 2026.

International OTC Healthcare: Segment revenues grew by 6.9% to $39.5 million in Q1 fiscal 2027, up from $37.0 million in the prior year period. This increase was primarily due to a $1.4 million contribution from the Breathe Right® brand acquisition. The contribution margin for this segment was $14.5 million in Q1 fiscal 2027, an increase from $13.9 million in Q1 fiscal 2026.

Outlook / Guidance

Prestige Consumer Healthcare Inc. is raising its fiscal 2027 outlook for both revenue and adjusted diluted EPS due to recent acquisitions. The company now anticipates full-year fiscal 2027 revenue to be between $1,290 million and $1,315 million, with an Adjusted Diluted EPS outlook of $4.55 to $4.65. Additionally, the Adjusted Free Cash Flow outlook for fiscal 2027 has been raised to $270 million or more, from the initial projection of $250 million or more.